NCT Research

Clinical Cancer Research Program in Lung Cancer


The NCT Clinical Lung Cancer Research Program is a leading center for multidisciplinary patient care with approximately 1200 lung cancer patients and ~1200 surgical procedures per year. A clinical trials unit currently performs 15 phase I-III trials (Kreuter Ann Oncol 2013). Strong interdisciplinary collaborations (DKFZ, EMBL, LungSys BMBF, EU CANCERALIA project, German Center for Lung Research) focus on: (1) mechanisms of lung cancer development and spread; (2) resistance; and (3) impact of interventions in palliative care (Shaw N Engl J Med 2013; Pfeifer Nat Genet 2012; Kaduthanam Lung Cancer 2013; Gottschling Lung Cancer 2012; Gottschling Lung Cancer 2013; Warth J Clin Oncol 2012).

CCRP Lung Cancer

Scientific Goals

  • Prospective validation of molecular signatures for prediction and treatment stratification with sequential tumor tissue acquisition (STTA).
  • Development of novel therapeutic strategies as a major network partner (national, international) in designing and conducting clinical trials and biomarker assessment.
  1. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M: Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol, 22: 986-92, 2013.
  2. Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann H, Muley T, Kuner R: Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer, 80:223-7, 2013.
  3. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H, Weichert W: The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol, 30: 1438-46, 2012.
  4. Wu H, Haag D, Muley T, Warth A, Zapatka M, Toedt G, Pscherer A, Hahn M, Rieker RJ, Wachter DL, Meister M, Schnabel P, Müller-Decker K, Rogers MA, Hoffmann H, Lichter P: Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. Genes Chromosomes Cancer, 52:250-64, 2013.
  5. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sänger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet, 44:1104-10, 2012.